Unless corrected, the Federal Circuit’s ruling in GSK v. Teva widely threatens the ability of generic and biosimilar developers to deliver more affordable medicines to patients in as timely a manner as possible.
Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.